Live Breaking News & Updates on Ilead sciences

Stay informed with the latest breaking news from Ilead sciences on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ilead sciences and stay connected to the pulse of your community

MAIA Biotechnology Appoints Leading Immuno-Oncology

New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbuster products CHICAGO, IL, Feb. ...

Romania , Chicago , Illinois , United-states , Switzerland , Cluj , Bern , American , Remus-vezan , Global-clinical-development-at-beigene , University-of-bern , European-hematology-association

GLAAD Celebrates LGBTQ+ Artists Of Color In Music With 2024 EMEI Cohort

GLAAD, the leading LGBTQ+ media advocacy organization, has unveiled the 2024 cohort for the Equity in Media and Entertainment Initiative’s sophomore year. It focuses on spotlighting LGBTQ+ music artists of color, highlighting their significant talent and contributions to the music and entertainment scene.

Kayla-thompson , Julianj-walker , Siaria-shawn , Albanus-thierry , Mylah-muse , Entertainment-initiative , Gilead-sciences , Academy-proud , Media-department , Recording-academy , Shawn-usher , Senior-director

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

BEIJING, February 19, 2024--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibo

Shanghai , China , United-states , San-francisco , California , Beijing , Haimen-jiangsu , Yuelei-shen , Gilead-sciences-inc , Biocytogen-fully-human-antibody-library , Biocytogen-pharmaceuticals-beijing-co-ltd , Biocytogen-pharmaceuticals

Gilead's $4.3B CymaBay Acquisition Adds Liver Disease Drug Under FDA Review

Acquiring CymaBay Therapeutics gives Gilead Sciences another drug for its liver disease portfolio. CymaBay’s molecule, seladelpar, is under FDA review for treating primary biliary cholangitis, a rare disease affecting the bile ducts of the liver.

Foster-city , California , United-states , Italy , Italian , Andy-hsieh , William-blair , Johnson , Novo-nordisk , Gilead-sciences , Intercept-pharmaceuticals , Cymabay-therapeutics

Safety Risks and FDA Hold Lead Gilead to Stop Work on Drug in Blood Cancers

Gilead Sciences said an independent review of interim Phase 3 data found the immunotherapy, magrolimab, led to a higher risk of death. Though Gilead is discontinuing further development of the drug in blood cancers, a review is ongoing in solid tumors.

Pfizer , Gilead-sciences , Forty-seven , Trillium-therapeutics , Weight-loss , Besity , Verweight , Diabetes , Massachusetts , Medical-devices , Obesity

FDA Calls for New Safety Warning for the Class of CAR T Cancer Therapies

Two months after announcing an inquiry into reports of new cancers in patients treated with CAR T-cell therapies, the FDA is directing makers of these therapies to add new safety warnings to product labels describing this risk. Companies have 30 calendar days to comply.

Johnson , Bristol-myers-squibb , Gilead-sciences , Novartis , Myers-squibb , Weight-loss , Besity , Verweight , Diabetes , Massachusetts , Medical-devices

Gilead Drug Fails Pivotal Lung Cancer Study, But Still Might Have Path Forward

Gilead Sciences said even though Trodelvy missed the main goal of its Phase 3 test in non-small cell lung cancer, the drug’s preliminary results show numerical improvement in patients whose disease did not respond to prior treatment with immunotherapy. The company plans to discuss with regulators a possible path forward in these patients.

Daiichi-sankyo , Daina-graybosch , Astrazeneca , Sales-for-gilead-sciences , Gilead-sciences , Weight-loss , Besity , Verweight , Diabetes , Massachusetts , Medical-devices , Obesity

What Makes Gilead Sciences (GILD) an Attractive Investment?

ClearBridge Investments, an investment management company, released its “ClearBridge Dividend Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The market recovered in 2023 following a sharp decline in 2022, driven by excitement about artificial intelligence and an improving forecast for interest rates. The strategy underperformed the benchmark S&P 500 […]

Nasdaq , Gilead-sciences-inc , Popular-stocks-among-hedge , Gilead-sciences , Clearbridge-investments , Ilead-sciences , Nc- , Ourth-quarter , Ividend-strategy , Nvestor-letter , Learbridge-dividend-strategy

Netflix Gave An Unproven Director $55 Million For A Sci-Fi Series, And He Blew It On Rolls-Royces, Crypto, And Dodgy Stock Bets

Carl Erik Rinsch never finished a single episode of "Conquest" for Netflix

Budapest , Hungary , Hollywood , California , United-states , Keanu-reeves , Carl-erik-rinsch , Gabriela-ros , Ferrari , Gilead-sciences , Charles-schwab , Netflix

15 Best Drug Stocks To Invest In

In this article, we discuss the 15 best drug stocks to invest in. You can skip our detailed analysis of the drug and pharmaceutical sector and its outlook this year, and go directly to read the 5 Best Drug Stocks To Invest In. Healthcare expands on the defensive concept, encompassing a myriad of companies. This […]

China , Ohio , United-states , Foster-city , California , United-kingdom , Sweden , New-york , Dublin , Ireland , London , City-of